Striving to make Canadian industries more competitive in the global marketplace by helping them generate and commercialize innovative products is the right aim, but the Conservative approach will do more harm than good if it continues to take money away from basic scientific research.
Rx&D, BIOTECanada say intellectual property proposals will protect Canadian innovation and attract capital, but harmonization with EU could put generic drug and regenerative medicine industries at a disadvantage.
Download policy briefing
People. Policy. Politics. This is an exclusive subscriber-only PDF.